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1. Introduction 
Pancreatitis is a common clinical entitiy with multiple contributing etiologies1. Triglyceride 
(TG) levels greater than 1000 mg/dL are seen in a small but significant number of cases of 
acute pancreatitis (AP), with estimates ranging between 1-7% of all cases and perhaps 
slightly higher in patients who present during pregnancy2-4. The clinical presentation of 
hypertriglyceridemic pancreatitis (HTGP) is similar to other causes of acute pancreatitis, but 
some evidence suggests that there may be an increased severity and risk of complications5,6. 
Multiple etiologies of highly elevated TG levels have been implicated, including congenital 
disorders, metabolic perturbations and certain medications but a definitive treatment 
regimen for profoundly elevated serum TG in association with acute, and often severe, 
pancreatitis has yet to be demonstrated7-10.  
Dietary restriction is the cornerstone of therapy. Additional treatment modalities have 
included insulin and heparin to stimulate the synthesis, release and activation of lipoprotein 
lipase (LPL) from capillary endothelial cells to promote TG degradation into free fatty acids 
for further metabolism or storage11. We present a case of HGTP managed with insulin, 
heparin and octreotide with dramatic results; a logarithmic decrease in serum TGL 
magnitude and a significant reduction in the time to resolution as compared with previous 
reports of treatment with insulin and heparin alone. Recent advances in the management of 
HGTP, including proposed mechanisms, will be reviewed. Adjunctive therapies, including 
plasmapheresis and more chronic therapy with lipid lowering agents and dietary 
modification will be discussed.  
2. Case report 
A 51-year-old Hispanic man presented to the emergency department with 2 days of 
epigastric pain radiating to the back. The patient reported one episode of emesis but denied 
fever, chills, dyspnea, diarrhea, or constipation. His past medical history was significant for 
asthma and gastroesophageal reflux disease. Medications included omeprazole daily and as 
needed acetaminophen, ibuprofen, and albuterol. Social history was significant for tobacco 
use, one pack per month, and ethanol use, two cans of beer daily. 
Temperature was 97.6F. Blood pressure was 117/72 mm Hg, heart rate 80 min, regular, and 
respiratory rate was 18/min. Examination of the cardiopulmonary and nervous system was 
unremarkable. The abdomen was diffusely tender without rebound, guarding or 
discoloration. No xanthelasmas, eruptions, arcus, or xanthomas were noted. Relevant 
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laboratory measurements from lipemic serum are listed in Table 1. The urine toxicology 
screen was positive for barbiturates. Cardiac screening (enzymes, electrocardiogram) was 
negative and ultrasound imaging revealed no abnormalities of the gall bladder, common 
bile duct, or pancreas. A CT scan performed on the second hospital day was remarkable for 
peripancreatic fat stranding without necrosis or hemorrhage. 
 
Analyte Reference Range Admission 24 h 48 h 
Amylase 25-125 U/L 80 126 141 
Lipase 23-203 U/L 179 166 96 
Glucose 74-118 mg/dL 100 83 93 
Triglycerides 30-190 mg/dL 20891 1423 355 
Cholesterol 60-160 mg/dL 862 997 594 
Sodium 136-144 mmol/L 111 121 140 
AST <40 IU/L 737 186 74 
ALT <33 IU/L 227 135 39 
Table 1. Laboratory Values at Presentation and While Hospitalized 
The patient was diagnosed with HTGP and initial management included elimination of 
enteral intake, aggressive fluid repletion, and opiate analgesia. Subsequent therapy included 
a continuous insulin infusion, a 10% dextrose infusion titrated to maintain euglycemia, 60 
U/kg unfractionated heparin intravenous (IV) bolus every 4 hours, and 100g octreotide 
bolus subcutaneously every 8 hours. TG fell by 2 orders of magnitude in 2 days, falling from 
21,000 to 355 mg/dL, the rest of the laboratory values were improved (Table 1), and the 
lipemia resolved. The clinical course was uncomplicated and the patient was discharged 
after 4 days.  
3. Clinical presentation of hypertriglyceridemic pancreatitis 
The clinical features of acute HTGP are similar to that of other causes of pancreatitis12. 
Patients may present with sudden and severe epigastric abdominal pain often accompanied 
by anorexia and profound nausea lasting hours to days13. Other less common findings, more 
indicative of chronic hyperlipidemia, include the presence of eruptive xanthomas over the 
extensor surfaces, lipemia retinalis, arcus and hepatospenomeglay due to fatty infiltration of 
the liver.14 Frequently, those presenting with significant TG elevations and pancreatitis have 
an underlying metabolic abnormality in lipid metabolism15,16. Patient presentations where 
HTGP is encountered include poorly controlled diabetics with or without a history of HTG, 
alcoholics with hypertriglyceridemia or lactescent serum on admission, non-diabetic, non-
obese patients with drug or diet-induced HTG and patients presenting with AP without 
secondary risk factors; the first three of these comprise the majority of clinical presentations 
of HTGP12,17,18.  
Following the onset of HTGP, TGL tend to fall rapidly over 72 hours in the fasting state as a 
result of decreased supply and absorption of chylomicrons19. In addition, VLDL secretion 
from the liver is reduced secondary to the administration of hypocaloric intravenous fluids, 
thus leading to a direct reduction in TGL20. 
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4. Lipid physiology 
Lipoproteins are macromolecules containing both organic proteins and bound lipids that are 
found in plasma in varying proportions and can be separated by density via 
ultracentrifugation. In increasing order of density, these separate into layers of 
chylomicrons, very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), 
low density proteins (LDL) and high density lipoprotein (HDL)21. 
 
 
Fig. 1. Fat metabolism 
http://www.britannica.com/bps/media-view/92255/0/0/0 
TG are a major lipid constituent of chylomicrons and VLDL. The former contains Apo B-48 
and is derived from dietary sources while the latter contains Apo B-100 and is liver 
generated22,23. Cholesterol is the primary component of IDL and LDL24. 
Dietary TG are absorbed through the brush border of intestinal enterocytes, incorporated 
into chylomicrons and pass through the basolateral aspect where they enter the lymphatics 
before entering the venous circulation via the thoracic duct, ultimately acquiring 
apolipoprotein C-II, a critical cofactor for lipoprotein lipase (LPL)25.  
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Both chylomicrons and VLDL are transported to muscle and adipose tissue where they are 
metabolized by LPL to meet energy demands or stored for future use26,27. LPL is secreted 
into the venous circulation by parenchymal cells in many tissues, migrates through the 
vasculature and anchors to the capillary endothelium via a heparan sulfate chain. Upon 
activation, it facilitates lipoprotein binding and TG degradation28. This process results in the 
release of fatty acids and acylglycerols which can then be utilized directly by myocytes to 
meet metabolic demands or be reincorporated into triglyceride for storage in adipocytes29.  
5. Diagnosis and laboratory evaluation 
The clinical presentation and course of HTG pancreatitis does not differ greatly from other 
causes of AP30. Lipemic serum, frequently associated with an underlying metabolic 
abnormality or compromising medications, is the single most reliable clue that the 
pancreatitis is associated with or precipitated by hyperlipidemia31. Although the serum 
triglyceride threshold for considering HTGP is generally considered to be in the range of 
1000 mg/dL, the severity, clinical course and complication rate do not correlate with lipid 
levels. In a study of 43 patients with HTGP, no correlation was observed between admission 
HTG and APACHE II score, nor was there a relation between TG level and pancreatic 
inflammatory complications or ultimate patient outcome32.  
Historically, clinicians have relied on increases in levels of serum amylase, and/or lipase to 
secure the diagnosis of acute pancreatitis. Newer diagnostic modalities, such as urine 
trypsinogen, procarboxypeptidase A and carboxypeptidase A, are becoming more available 
and may become more relevant33-35. Some patients with HTG pancreatitis and lipemic serum 
present with spurious laboratory values that can complicate the diagnosis36 but a serum 
lipase sensitivity and specificity of 67% and 97% respectively, argue that this test remains a 
valuable diagnostic tool37. 
6. Pathophysiology of hypertriglyceridemic pancreatitis 
The mechanism by which elevated levels of plasma TG lead to the development of AP is not 
fully understood. It is generally accepted that levels greater than 1000 mg/dL are required to 
precipitate an episode of pancreatitis, but such levels of TG do not always cause HTGP.38 The 
most recent ATP III guidelines suggest that a normal TG level is considered to be less than 150 
mg/dl, while those greater than 500 mg/dl are considered very high39. Pancreatic lipase, a 
digestive enzyme concentrated in the exocrine pancreas which participates in TG degradation, 
may be liberated in AP and act in an unregulated fashion to contribute to tissue breakdown40. 
Additionally, if the local plasma TG level increases beyond the enzymatic capacity of the 
pancreas, free fatty acids begin to accumulate and can lead to injury of pancreatic acinar cells 
and surrounding tissues41,42. Altered pancreatic blood flow, perhaps aggravated by the 
hyperviscosity of chylomicronemia, may also create a more acidic environment in which free 
fatty acids become more toxic to the surrounding tissue43-46. The resultant cellular injury leads 
to further pancreatic inflammation, injury and destruction. 
7. Causes of hypertriglyceridemia 
Primary Causes: Primary causes of HTG consist of a series of genetic disorders leading to 
abnormalities in lipid metabolism and patients presenting with HTG or lipemic serum 
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should be evaluated for Frederickson classification dyslipidemias types I, IV and V as they 
are strongly associated with highly elevated serum TG47,48.  
Secondary Causes: 
Diabetes – Poorly controlled, or uncontrolled, diabetes is a common cause of HTGP49. In type 
1 diabetes mellitus, the paucity of insulin reduces LPL synthesis and thus compromises 
effective TG hydrolysis and release of free fatty acids. The latter are already accumulating in 
the absence of insulin-facilitated storage50,51. Similarly, in type 2 diabetes mellitus, increased 
insulin resistance leads to enhanced production and reduced clearance of TGs52. The causal 
role of diabetic ketoacidosis (DKA) in HTG was evaluated in a prospective study of 100 
patients with DKA, 11 of whom had AP, and of these, HTG was the only attributable cause 
in 4 cases53. Serum TG levels normalized in these patients after control of the acidosis.  
 
Primary HTG 
 Genetic: Frederickson type I, IV, V 
Secondary HTG 
  Diet: alcohol excess, weight gain/obesity 
  Drugs: exogenous estrogens, tamoxifen, retinoids, thiazides, beta blockers, protease 
inhibitors, propofol, parenteral lipid infusions 
  Disorders of Metabolism: Diabetes, pregnancy, chronic renal failure, hypothyroidism, 
porphyria 
*Adapted from Ref 12 
Table 2. Common Etiologies of HTG 
Alcohol – Ethanol compromises fuel and energy metabolism, thereby resulting in decreased 
serum glucose levels with elevated levels of lipids due to increased production and 
decreased utilization of energy sources. Alcohol can aggravate HTG and the liberated free 
fatty acid esters can promote calcium influx which leads to calcium-mediated pancreatic 
necrosis57. Nutritional deficiencies, including hypoglycemia, activated counterregulatory 
mechanisms and reduced cofactor availability reduce or inhibit insulin secretion, thus 
further compromising energy metabolism and exacerbating hyperlipidemia58. 
Medications- Several medications are known to increase plasma TG levels, including 
isotretinoin59, propofol60, protease inhibitors61 and furosemide62. Estrogens and Tamoxifen 
are two well studied drugs in which the tendency to promote HTG and steatohepatitis is 
well described63. 
Estrogen – Exogenous estrogens increase serum TG and fatty acids primarily by reducing 
levels of lipoprotein and hepatic lipases which subsequently decreases clearance and 
aggravates insulin resistance, perhaps by as much as 40%64-66. Goldenberg et al., evaluated 
56 female patients at a Cholesterol Center because of TG >400 mg/dl and/or HTGP, and/or 
failure of TG-lowering therapy. Of that cohort, 17 females (30%) had a history of AP and of 
those, 9 (53%) had taken, or were concurrently taking exogenous steroid hormones67. The 
authors concluded that hormone therapy remain relatively contraindicated with plasma 
TG>300mg/dl and strictly contraindicated when TG greater than >500 mg/dl in order to 
avoid an episode of pancreatitis.  
Tamoxifen – Tamoxifen is a non-steroidal anti-estrogen commonly used in the treatment of 
patients with breast cancer and has shown the ability to decrease LDL and total cholesterol 
levels. There is frequently an increase in VLDL synthesis and subsequent rise in plasma TG 
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levels due to reductions in lipoprotein lipase activity68,69. Elisaf, et al., reported 12 patients 
with serum TG >1000 mg/dl who were observed after administration of 20mg/day of 
tamoxifen70. Four of these patients, two of whom had a personal or family history of 
hyperlipidemia, developed HTGP. This led them to the conclusion that, like synthetic 
estrogens, the tamoxifen-mediated rise in TGs may be either contributory or causative in the 
development of AP.  
Pregnancy – Gestational AP is an uncommon condition, with studies ranging incidence 
between 1 in 3,500-4,000 pregnancies71. Most cases of AP during pregnancy are mild and are 
most often attributable to biliary disease, while severe AP most commonly results from 
hypertriglyceridemia and tends to occur in the second and third trimesters72. During 
pregnancy there is a physiologic increase in plasma lipids. Cholesterol and TG increase due 
to an increased production of VLDL and the decreased actions of LPL and hepatic lipase73.  
HTGP tends to develop in women with an underlying disorder in lipid metabolism, such as 
LPL74 or apolipoprotein C-II deficiency75. Maternal mortality in cases complicated by HGTP 
is estimated to be near 20% and cause of death has been linked to the pancreatitis itself, or, 
rarely, has been associated with HELLP syndrome.76 The mainstay of treatment, as in the 
non-pregnant state, is early recognition and intervention77,78. A major difference in long term 
management is that the use of HMG-CoA reductase inhibitors (statins) is contraindicated in 
pregnancy as they are a teratogenic category X pharmaceutical79.  
 
 Type I Type IV Type V 
Elevated lipoproteins Chylomicrons VLDL VLDL 
Chylomicrons 
Cholesterol Normal Normal or Increased Normal 
Triglycerides +++ ++ +++ 
Plasma appearance † Clear plasma, creamy 
supernatant 
Turbid Turbid plasma, creamy 
supernatant 
Genotype LPL deficiency 
Apo C-II deficiency 
FCH 
Sporadic HTG 
Familial HTG 
Age of onset (primary 
form) 
Infancy or childhood Usually adulthood Usually adulthood 
Xanthomas ‡ Eruptive or tuberous None usually Eruptive or tuberoeruptive 
Other clinical features Recurrent abdominal pain 
Pancreatitis 
Lipemia retinalis 
Hepatosplenomegaly 
Premature CAD 
Pancreatitis 
Obesity 
Glucose intolerance 
Arthritic symptoms 
Gall bladder disease 
Hyperuricemia 
Recurrent abdominal pain 
Pancreatitis 
Lipemia retinalis 
Hepatosplenomegaly 
Peripheral paresthesis 
Glucose intolerance 
Hyperuricemia 
*Adapted from Reference 12 
† Plasma obtained after 12 hours of fasting, left undisturbed in refrigerator overnight 
‡Seen only in a minority of patients, frequency increases as plasma lipid levels rise 
LPL, lipoprotein lipase; HTG, hypertriglyceridemia; Apo C-II, apolipoprotein CII; CAD, coronary 
artery disease; FCH, familial combined hyperlipidemia.  
Table 3. Familial Hyperlipidemias* 
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Hypothyroidism – HTG is common in hypothyroidism, having been reported in up to 35% of 
cases80. Decreased free thyroid hormone increases the synthesis of LPL and decreases 
hepatic lipase activity with a net tendency toward increased plasma TG levels, perhaps 
further complicated by the down-regulation of LDL receptors81-84. One patient with central 
hypothyroidism secondary to a craniopharyngioma developed HTG with a level of (3,300 
mg/dL) which precipitated an episode of AP85. 
8. Treatment 
Initial Management – Initial management of patients presenting with HTGP mirrors that of 
other causes of AP86. Patients should be placed on bowel rest, receive nothing by mouth and 
undergo aggressive fluid resuscitation due to third space losses87. Adequate pain control is 
essential, often through the use of opioid narcotics88-90. Some controversy still remains about 
the potential for medication-induced sphincter of Oddi dysfunction aggravating the clinical 
picture although low dose transdermal fentanyl patches appear do not to compromise 
sphincteric function91,92. Meperidine has been used as an alternative analgesic to treat pain in 
those suffering from acute pancreatitis, but concern for the production of toxic metabolites has 
altered prescribing practices93-95. Enteral nutrition should be resumed as soon as is practical, 
recognizing that the reintroduction of fats, the building blocks of chylomicrons, may be 
deleterious96-100. Assessment of exocrine function prior to refeeding may be prudent, given that 
pancreatic destruction has the potential to compromise secretion of digestive enzymes101. 
Beyond initial management, HTGP therapy must include measures to reduce serum TG, 
both acutely and following the episode to minimize the risk of recurrence102. Laboratory 
tests including liver function tests, glucose, renal function, thyroid stimulating hormone and 
urine protein should be obtained to rule out secondary causes of HTG103. Specific tests 
documenting LPL or Apo C-II deficiency should be obtained if type I hyperlipidemia is 
suspected104-107. No standard treatment guidelines yet exist in the specific treatment of 
HTGP although a rational treatment strategy should include rapidly lowering serum TG, 
blocking the induction of pro-inflammatory mediators that lead to pancreatic destruction 
and reducing the likelihood of recurrence by eliminating offending agents, as is possible, 
and through the use of antihyperlipidemic medications108-111.  
Insulin – Intravenous insulin administration is an effective therapy for patients diagnosed 
with HTG induced pancreatitis, including those with and without diabetes mellitus112,113. 
VLDL is a triglyceride-rich lipid moiety and the use of insulin decreases hepatic production 
of apolipoprotein B-100 rich VLDL1 and intestinal production of VLDL2, rich in apoprotein 
B-48 while also increasing hydrolysis of TG by LPL114,115. Insulin promotes storage of both 
glucose and fatty acids, thus a continuous infusion of insulin should reduce serum levels of 
both of these fuels116,117. Intravenous (IV) insulin may be considered more effective and 
easier to titrate than subcutaneous (SQ) administration based upon absorption and delivery 
kinetics, although both have been used with some success104,118,119. Insulin has been used 
alone, but is commonly used in conjunction with other TG lowering modalities120,121. 
Mikhail et al. reported lowering TG from 7,700 mg/dL to 246 mg/dL in one patient using 
only intravenous insulin at 3-9 units per hour for 4 days while maintaining euglycemia122. In 
the same report, a second patient treated in a similar fashion saw TG levels drop from 10,500 
mg/dL to 656 mg/dL over 4 days using 4 units SQ insulin (Lispro) every four hours.  
Although no standard protocol for insulin administration in the context of HTGP has been 
defined, the authors have achieved success with insulin doses titrated from an initial rate of 
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0.1-0.4 units/kg per hour. Once an effective insulin infusion dose has been achieved, we 
have kept this constant while the dextrose infusion is titrated to maintain euglycemia, 
contrary to what is usually done when insulin is infused. 
Heparin – Heparin is an effective treatment in the management of elevated TG in the 
presence of HTGP123. LPL, the enzyme which hydrolyzes TG rich lipoproteins, is normally 
bound by a heparan sulfate proteoglycan chain to the capillary endothelium124. Heparin, 
when administered in a bolus dose, has a stronger affinity for the LPL binding site than does 
the heparan sulfate, leading it to dissociate from the endothelium tissue into the plasma as a 
heparan-LPL complex.125 This surge of “free” LPL is then able to bind and metabolize 
lipoproteins at an accelerated rate, thus lowering serum TG levels126. Although there is an 
initial rise in available LPL, there is also a peaking of activity, after which, LPL activity 
begins to wane as the enzyme is transported and degraded in the liver127. This heparin-
stimulated increase and then reduction in LPL activity can be minimized by the use of 
intermittent heparin dosing and results in an initial drop in serum TGs, but then followed 
by a gradual increase128,129. This phenomenon tends to be more pronounced with the use of 
LMW heparin, versus un-fractionated heparin, although studies have shown both 
preparations capable of lowering severely elevated TG in the setting of HTGP.130  
Heparin has been used as successful monotherapy in treatment of profound HTG in 
previous studies131-133; however, more dramatic results have been achieved when used in 
combination with other modalities (Table 4). At present, no studies have been conducted as 
to the best route of administration (IV or SQ) or dosage in the treatment of HTGP. It is the 
opinion of the authors that bolus dosing of IV heparin 18 units/kg134 dosed every 4-6 hours 
is more effective than continuous administration.  
 
Patient Trig Level 
(mg/dL) at 
Admission 
IV Insulin U/h: IV Heparin Units;  
SC Octreotide g 
Triglyceride 
Results 
41-year-old 
female ETOH 
abuse 
7037 Insulin 1-5 U/h for 5d; heparin 500-
900 U/h for 3d 
5111 mg/dL 
by day 3 
51-year-old male 
ETOH abuse 
7900 Insulin 12 U/h; heparin 5000 U b.i.d 670 mg/dL by 
day 4 
31-year-old 
female at 30 wk 
gestation 
4445 Insulin 20 U/h; heparin 10,000 U/24h 880 mg/dL by 
day 3 
51-year-old* 
ETOH abuse 
21,000 Insulin 2 U/h minimum; heparin 60 
U/kg every 4h; octreotide 100 g 
subcutaneously every 8 h 
355 mg/dL in 
48 hr 
*Our patient. 
Adapted from Ref 122 
Table 4. Published Reports of Management of Hypertriglyceridemia With IV Insulin and 
Heparin: Comparison to Case Patient 
Octreotide™ – Somatostatins, also called somatotropin release inhibitory factors (SRIFs) are 
cyclic peptide hormones which exist in 2 forms, SRIF14 (14 amino acids) and SRIF28 (28 
amino acids)135, and are synthesized in several sites within the body, including the central 
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nervous system, pituitary, gastrointestinal (GI) tract, liver, pancreas, and urogenital 
system135,136. SRIFs bind to 6 subpopulations of somatostatin receptors (sstrs) (1, 2A, 2B, 3, 4, 
5) located both peripherally and centrally137. The sstr 2B receptor has been demonstrated in 
rodents but not unequivocally in humans138. Binding of somatostatins to each of these 
receptors leads to the inhibition of adenylate cyclase via a pertussis toxin sensitive G-
protein(Gαi) and, at agonist concentrations greater than 1-nM, there is stimulation of 
phospholipase C which increases calcium ion mobilization139. In neuroendocrine cells, sstrs 
2,3,4 and 5 bind to inward rectifying potassium channels140. 
SRIFs inhibit the secretion of several GI tract hormones including insulin, glucagon, gastrin, 
cholecystokinin, vasoactive intestinal peptide and secretin and also inhibit exocrine gastric 
acid, pepsin, pancreatic enzymes, bile and intestinal fluid secretions 141. The pancreas 
expresses sstrs on both acinar cells (sstr4, sstr5)142 and islet cells (sstr1 > sstr5 > sstr2 > sstr3 
> sstr4)143. In rodents, sstr2 in the dorsal vagal complex exerts some control of pancreatic 
exocrine secretion144.  
Octreotide, a somatostatin analog, has particular affinity for types 2A, 2B and somewhat for 
sstr5145. Octreotide has been used in the treatment of pancreatitis with varying degrees of 
success146. The evidence that pancreatic sstrs are down-regulated in acute pancreatitis 
suggests that the mechanisms of action of octreotide therapy may include both receptor and 
non-receptor mediated mechanisms147. Secretion of insulin and glucagon are inhibited by 
agonists of sstr2, sstr5, and sstr1148. Inhibition of glucagon secretion with octreotide therapy 
may potentiate the fatty acid storing action of insulin and lead to a greater reduction of 
serum TG149. Octreotide’s effect on the hypoglycemic counter regulatory system, notably the 
hyperglycemic actions of glucagon, necessitates the co-administration of dextrose and 
frequent monitoring of glucose levels to maintain euglycemia.  
 
Study No. of patients
No. of patients with 
complete recovery (%) 
Mortality (%) 
Yeh et al. 17 13(76.5) 2 (11.8) 
Kyriakidis et al. 10 9 (90) 1 (10) 
Kadikoylu et al. 7 7 (100) 0 
Lennertz et al. 5 5 (100) 0 
* Adapated from Ref 5 
Table 5. Apheresis in hypertriglyceridemic pancreatitis * 
Plasmapheresis – Although the primary methods of treating HTGP are dietary fat restriction 
and lipid lowering medications, these treatments may be inadequate in the setting of severe 
acute HTGP150,151. Plasmapheresis has been used with some measure of success and is 
thought to work through two mechanisms: the removal of serum TG from the patient’s 
serum and the supplementation of LPL and apolipoprotein found in the fresh frozen plasma 
of the donor plasma152,153. Yeh, et. al found that a single exchange removed 66.3% of TG, 
while a second exchange removed 83.3% of serum TG154. The number of sessions, however, 
did not correlate with clinical outcome. Syed et al., evaluated patients with HTGP receiving 
plasmapheresis and observed an average reduction in TG levels of 89.3% with the first 
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treatment, but found no clear relationship between APACHE II scores or length of hospital 
stay155. 
Plasmapheresis is not without risk, and at this time its use in HTGP remains undefined. 
Potential complications or adverse reactions include allergic reaction and transfusion related 
infections. One patient undergoing plasmapheresis was reported to develop anaphylactoid 
shock154,156. At present the American Society for Apheresis Guidelines of 2007 places apheresis 
in its role for HTGP as a category three due to limited data and conflicting reports157.  
Apheresis Recommendations* 
Category Recommendation 
I First line therapy 
II Second line therapy 
III Specific role not determined 
IV Not recommended 
*Journal of Clinical Apheresis, Special Issue(Vol 25, 2010) 
9. Long-term management 
Diet and General Precautions –Primary causes of hyperlipidemia often require medications 
but, where possible, reducing the impact of secondary causes with therapeutic lifestyle 
changes such as reducing alcohol intake, weight reduction, improved diabetic control and 
discontinuing precipitating medications are all vital steps158. Dietary advice should be 
obtained through a certified nutritionist, but fat consumption should be reduced to 7% of 
total caloric intake, cholesterol limited to 200mg and trans fatty acid intake should be 
limited159. Medium chain TG are an improved source of fat calories as they are absorbed 
directly into portal circulation and do not require chylomicrons for hepatic uptake and 
lower TG levels at the cost of a slightly elevated cholesterol level160. A meta-analysis 
performed by Dattilo and Kris-Etherson observed a strong correlation between weight loss 
and decrease in plasma TG levels.161  
Medications: 
Fibrates - Fibric acid derivatives are a class of medications which bind to peroxisome 
proliferator alpha (PPARα) receptors and are capable of increasing serum HDL while 
simultaneously lowering TG and are an effective adjunct in treating patients with HTGP 
who cannot be managed with diet alone162. They are typically used in treating primary HTG 
and include drugs such as gemfibrozil, bezafibrate and fenofibrate163. Fibrates lower serum 
TG by increasing the levels of LPL and hepatic lipase, reducing levels of Apo CIII, which 
down-regulates LPL activity, and by increasing fatty acid uptake by the liver164,165. Toxicities 
include elevated liver enzyme levels, cholelithithiasis, myalgias and rhabdomyolysis; the 
last two of these are more common when used in patients with impaired renal function166. 
Two cases have been reported where patients developed pancreatitis while taking fibrate or 
fibrate-statin combinations.167, 168 It is unclear whether the cause of the pancreatitis was 
directly related to the drug itself, a failure of treatment or possibly through the formation of 
biliary sludge or gallstone formation.  
Niacin – Niacin, a B vitamin somewhat less potent than the fibric acids, decreases TG levels 
by reducing hepatic secretion of VLDL and TG while raising HDL and lowering LDL levels, 
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an overall positive impact on the lipid profile169. When used as doses of 1,500mg/day, no 
adverse impact on glucose metabolism is seen but significant prostaglandin D2-mediated 
flushing limits the clinical utility of this drug170.  
Statins – HMG-CoA reductase inhibitors (statins) are not the preferred method for lowering 
serum TG as their role in lipid management remains in prevention (primary and secondary) 
of coronary artery disease in the presence of elevated cholesterol, but only mild to moderate 
triglyceride elevations171. Statins are not suitable monotherapy for long-term management of 
HTG, however, they may have some synergistic benefit when combined with fibrates172,173. 
Omega 3 Fatty Acids – Fish oils and omega-3 fatty acids are effective adjuncts to other drug 
therapy as they lead other drug therapy as they lead to a decrease in VLDL and lower 
endogenously derived TG-rich lipoproteins174,175. Active TG lowering molecules in these 
supplements include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)176. 
Omega-3 fatty acids were studied in a prospective, double-blinded trial and were able to 
lower TG levels, ranging from 500-2,000 mg/dL, by an average of 45%177. The minimum 
effective dose is approximately 1 g/d; however, a dose of 3 to 4 g/d has shown to reduce 
serum TG by 30-50% in hyperlipidemic patients178.  
10. Conclusion  
HTG is a significant cause of AP, with most estimates ranging from 1-7% of all cases. 
Presentation is often similar to other forms of AP, with lipemic serum usually the only 
distinguishing initial sign. Clinicians should routinely test TG levels in patients with 
suspected or confirmed AP, especially those who have a history of diabetes, alcoholism, 
obesity, are taking a known precipitating medication, are pregnant or display normal 
amylase in the presence of elevated lipase.  
To date, there are no official guidelines for the treatment of HTGP, although a number of 
different treatment modalities have been employed to rapidly lower the serum TG, 
including insulin, heparin, fibric acids and omega 3 fatty acids. Plasmapheresis can also 
rapidly lower serum TG levels, but significant potential side effects and lack of rigorous 
proof of efficacy have yet to clarify its role in treatment of HTGP. Long term management 
with diet modification and anti-hyperlipidemic medications such as statins, niacin and 
omega-3 fatty acids are excellent adjuncts in controlling TGs in patients with HTGP and 
preventing potential recurrences.  
We have achieved dramatic effects with the combination of insulin, heparin and octreotide, 
a reduction in TG levels of two orders of magnitude in 48 hours, results unprecedented in 
the literature. These results, while impressive, have yet to be reproduced and one must 
remain appropriately circumspect when interpreting this case report. It is also important to 
note that the positive barbiturate level may have unmasked an inducible porphyria and that 
rapid resolution of HTGP was aided by the removal of this compound from the metabolic 
milieu. No clear treatment algorithm exists for the management of HTGP and well-
designed, controlled, prospective studies are needed to clearly delineate the ideal regimen. 
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Acute Pancreatitis (AP) in approximately 80% of cases, occurs as a secondary complication related to
gallstone disease and alcohol misuse. However there are several other different causes that produce it such
as metabolism, genetics, autoimmunity, post-ERCP, and trauma for example... This disease is commonly
associated with the sudden onset of upper abdominal pain that is usually severe enough to warrant the patient
seeking urgent medical attention. Overall, 10-25% of AP episodes are classified as severe. This leads to an
associated mortality rate of 7-30% that has not changed in recent years. Treatment is conservative and
generally performed by experienced teams often in ICUs. Although most cases of acute pancreatitis are
uncomplicated and resolve spontaneously, the presence of complications has a significant prognostic
importance. Necrosis, hemorrhage, and infection convey up to 25%, 50%, and 80% mortality, respectively.
Other complications such as pseudocyst formation, pseudo-aneurysm formation, or venous thrombosis,
increase morbidity and mortality to a lesser degree. The presence of pancreatic infection must be avoided.
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